Biological imaging and the molecular basis of dopaminergic diseases

Biochemical Pharmacology

Volumn 54, Issue 3, 1997, Pages 341-348

  Barrio, Jorge R ^a   Huang, Sung C ^a   Phelps, Michael E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

6 18F fluoro L DOPA; Dopaminergic mechanisms; Positron emission tomography

Indexed keywords

6 FLUORODOPA F 18;

DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; HUMAN; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 0030803658     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00031-2     Document Type: Note

References (94)

1. Langston JW, Predicting Parkinson's disease. Neurology 40 (Suppl 3): 70-74, 1990.
2. Brooks DJ, Parkinson's disease - A single clinical entity? Q J Med 88: 81-91, 1995.
3. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F and Agid Y, Striatal dopamine deficiency in Parkinson's disease: Role of aging. Ann Neurol 26: 551-557, 1989.
4. Seeman P and Niznik HB, Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 4: 2737-2744, 1990.
5. Koob GF and Bloom FE, Cellular and molecular mechanisms of drug dependence. Science 242: 715-723, 1988.
6. 3H]amphetamine with rat brain synaptosomes. II. Active transport. J Pharmacol Exp Ther 257: 830-835, 1991.
7. German DC, Manaye K, Smith WK, Woodward DJ and Saper CB, Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization. Ann Neurol 26: 507-514, 1989.
8. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM and Kopin IJ, A primate model of Parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546-4550, 1983.
9. Albanese A, Granata R, Gregori B, Piccardi MP, Colosimo C and Tonali P, Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioral, morphological and biochemical correlates. Neuroscience 55: 823-832, 1993.
10. Langston JW, Ballard P, Tetrud JW and Irwin I, Chronic parkinsonism in humans due to a product of meperidineanalog synthesis. Science 219: 979-980, 1983.
11. Tanner CM, The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci 12: 49-54 1989.
12. Koller WC, When does Parkinson's disease begin? Neurology 42 (Suppl 4): 27-31, 1992.
13. Tetrud JW, Langston JW, Garbe PL and Ruttenberg AJ, Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology 39: 1483-1487, 1989.
14. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, Oakes D and the Parkinson's Study Group. Markers of dopamine metabolism in Parkinson's disease. Neurology 42: 2111-2117, 1992.
15. Langston JW and Koller WC, The next frontier in Parkinson's disease: Presymptomatic detection. Neurology 41 (Suppl 2): 5-7, 1991.
16. M1 ganglioside treatment. Science 256: 843-846, 1992.
17. Barrio JR, Approaches to the design of biochemical probes for positron emission tomography. Neurochem Res 16: 1047-1054, 1991.
18. Garnett ES, Firnau G and Nahmias C, Dopamine visualized in the basal ganglia of living man. Nature 305: 137-138, 1983.
19. Garnett ES, Nahmias C and Firnau G, Central dopaminergic pathway in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 11: 174-179, 1984.
20. Calne DB, Langston JW, Martin WRW, Stoessl AJ, Ruth TJ, Adam MJ, Pate BD and Schulzer M, Positron emission tomography after MPTP: Observations relating to the cause of Parkinson's disease. Nature 317: 246-248, 1985.
21. Nahmias C, Garnett ES, Firnau G and Lang A, Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 69: 223-230, 1985.
22. 18F]-labeled 6-fluoro-L-dopa and positron emission tomography. Adv Neurol 45: 167-169, 1986.
23. Firnau G, Garnett ES, Chirakal R, Sudesh S, Nahmias C and Schrobilgen G, [F-18]Fluoro-L-dopa for the in vivo study of intracerebral dopamine. Int J Rad Appl Instrum 37: 669-675, 1986.
24. Martin WRW, Stoessl AJ, Adam MJ, Ammann W, Bergstrom M, Harrop R, Laihinan A, Rogers JG, Ruth TJ, Sayre CI, Pate BD and Calne DB, Positron emission tomography in Parkinson's disease: Glucose and dopa metabolism. Adv Neurol 45: 95-98, 1986.
25. Martin WRW, Palmer MR, Patlak CS and Calne DB, Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 26: 535-542, 1989.
26. 18F)Fluorodopa PET scanning in the ALS-PD complex of Guam. Neurology 37 (Suppl 1): 113, 1987.
27. Guttman M, Burns RS, Martin WRW, Peppard RF, Adam MJ, Ruth TJ, Allen G, Parker RA, Tulipan NB and Calne DB, PET studies of parkinsonian patients treated with autologous adrenal implants. Can J Neurol Sci 16: 305-309, 1989.
28. Leenders KL, Frackowiak RSJ and Lees AJ, Progressive supranuclear palsy (PSP) studied with positron emission tomography. Neurology 37 (Suppl 1): 113, 1987.
29. Leenders KL, Aquilonius S-M, Bergström K, Bjurling P, Crossman AR, Eckernas S-Å, Gee AG, Hartvig P, Lundqvist H, Långström B, Rimland A and Tedrorff J, Unilateral MPTP lesion in a rhesus monkey: Effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res 445: 61-67, 1988.
30. Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Wells TH, Barrett JN, Grafton ST, Huang SC, Eidelberg D and Rottenberg DA, Transplantation of human fetal dopamine cells for Parkinson's disease. Arch Neurol 47: 505-512, 1990.
31. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden D and Bjorklund A, Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 247: 574-577, 1990.
32. 18F]6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat. J Neurochem 48: 601-608, 1987.
33. 18F]fluoro-L-dopa in rats, monkeys and humans. Life Sci 47: 149-157, 1990.
34. 3H]L-dopa in rats. Biochem Pharmacol 39: 1853-1860, 1990.
35. 18F]Fluoro-DOPA metabolism in monkeys and humans: Biochemical parameters for the formulation of tracer kinetic models with positron emission tomography. J Cereb Blood Flow Metab 11: 890-897, 1991.
36. 18F]Fluoro-L-DOPA metabolism in MPTP-treated monkeys: Assessment of tracer methodologies for positron emission tomography. Brain Res 543: 271-276, 1991.
37. 18F-L-DOPA imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys. Exp Brain Res 78: 69-80, 1989.
38. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 48: 1077-1082, 1987.
39. 18F]fluoro-L-dopa kinetics in positron emission tomography. J Nucl Med 33: 1472-1477, 1992.
40. Garnett S, Firnau G, Nahmias C and Chirakal R, Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res 280: 169-171, 1983.
41. 18F]-6-fluorodopa during positron emission tomography: Elimination and metabolism in carbidopa treated subjects. Life Sci 39: 2243-2252, 1986.
42. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T and Marsden CD, Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49: 853-860, 1986.
43. 18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20: 258-262, 1986.
44. Patlak CS, Blasberg RG and Fenstermacher JD, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3: 1-7, 1983.
45. 18F]-fluorodopa uptake by carbidopa pretreatment. J Cereb Blood Flow Metab 9 (Suppl 1): S419, 1989.
46. 18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand 81: 24-30, 1990.
47. 18F]fluoro-L-DOPA in rat. J Cereb Blood Flow Metab 10: 707-719, 1990.
48. Christenson JG, Dairman W and Udenfriend S, Preparation and properties of a homogeneous aromatic-L-amino acid decarboxylase from hog kidney. Arch Biochem Biophys 141: 356-367, 1970.
49. 18F]fluoro-DOPA in human positron emission tomographic studies. J Cereb Blood Flow Metab 11: 898-913, 1991.
50. Gjedde A, Reith J, Dyve S, Leger G, Guttman M, Diksic M, Evans A and Kuwabara H, Dopa decarboxylase in the living human brain. Proc Natl Acad Sci USA 88: 2721-2725, 1991.
51. Brodie BB, Kuntzman R, Hirch CW and Costa E, Effects of decarboxylase inhibition on the biosynthesis of brain monoamines. Life Sci 1: 81-84, 1962.
52. Opacka-Juffry J and Brooks DJ, L-Dihydroxyphenylalanine and its decarboxylase: New ideas on their neuroregulatory roles. Mov Disord 10: 241-249, 1995.
53. Michael AC, Justice JB Jr and Neill DB, In-vivo voltammetric determination of the kinetics of dopamine metabolism in the rat. Neurosci Lett 56: 365-369, 1985.
54. Wood PL, Kim HS, Stocklin K and Rao TS, Dynamics of the striatal 3-MT pool in rat and mouse: Species differences as assessed by steady-state measurements and intracerebral dialysis. Life Sci 42: 2275-2281, 1988.
55. Doutechi M, Wang C and Costa E, Compartmentation of dopamine in rat striatum. Mol Pharmacol 10: 225-234, 1974.
56. Groppetti A, Algeri S, Cattabeni F, DiGiulio AM, Galli CL, Ponzio F and Spano PF, Changes in specific activity of dopamine metabolites as evidence of a multiple compartmentation of dopamine in striatal neurons. J Neurochem 28: 193-197, 1977.
57. Rossetti ZL, Silvia CP, Krajnc D, Neff NH and Hadjiconstantinou M, Aromatic-L-amino acid decarboxylase is modulated by D1 dopamine receptors in rat retina. J Neurochem 54: 787-791, 1990.
58. 14C]-L-DOPA labeling in forebrain mesolimbic structures of rat induced by self-stimulation of dopaminergic neurons in ventral segment area and substantia nigra. J Cereb Blood Flow Metab 11: S608, 1991.
59. 3H]L-DOPA striatal metabolism. Soc Neurosci Abstr 17: 501, 1991.
60. Hadjivonstantinou M, Rossetti Z, Silvia C, Krajnc D and Neff NH, Aromatic L-amino acid decarboxylase activity of the rat retina is modulated in vivo by environmental light. J Neurochem 51: 1560-1564, 1988.
61. 2-adrenoreceptors. J Neurochem 52: 647-652, 1989.
62. 18F]Fluoro-L-DOPA probes dopamine turnover rates in central dopaminergic structures. J Neurosci Res 27: 487-493, 1990.
63. Agid Y, Javoy F and Glowinski L, Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat. Nature 245: 150-151, 1973.
64. Hefti F, Melamed E and Wurtman RJ, Partial lesions of the dopaminergic nigrostriatal system. Biochemical characterization. Brain Res 195: 123-137, 1980.
65. Hefti F, Melamed E and Wurtman RJ, The site of dopamine formation in rat striatum after L-DOPA administration. J Pharmacol Exp Ther 217: 189-197, 1981.
66. Nissbrandt H and Carlsson A, Turnover of dopamine and dopamine metabolism in rat brain: Comparison between striatum and subtantia nigra. J Neurochem 49: 959-967, 1987.
67. Lloyd KG and Hornykiewicz O, Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J Neurochem 19: 1549-1559, 1972.
68. Bowsher RR and Henry DP, Aromatic-L-amino acid decarboxylase: Biochemistry and functional significance. In: Neuromethods, Series 1: Neurochemistry, Neurotransmitter Enzymes (Eds. Boulton AA, Baker GB and Yu PH), pp. 33-77. Humana Press, Clifton, NJ, 1986.
69. Albert VR, Allen JM and Job TH, A single gene codes for aromatic-L-amino acid decarboxylase in both neuronal and non-neuronal tissues. J Biol Chem 262: 9404-9411, 1987.
70. Ichinose H, Kurosawa Y, Titani K, Fujita K and Nagatsu T Isolation and characterization of a cDNA clone encoding human aromatic L-amino acid decarboxylase. Biochem Biophys Res Commun 164: 1024-1030, 1989.
71. Oldendorf WH, Brain uptake of radiolabeled amino acids amines, and hexoses after arterial injection. Am J Physiol 221: 1629-1639, 1971.
72. Wade LA and Katzman R, Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J Neurochem 25: 837-842, 1975.
73. Cheng D, Ph.D. Dissertation. University of California, Los Angeles, 1993.
74. Hardebo JE and Owman C, Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface. Ann Neurol 8: 1-11, 1980.
75. Owman C and Hardebo JE, Functional heterogeneity of the cerebrovascular endothelium. Brain Behav Evol 32: 65-75, 1988.
76. Bertler A, Falck B and Owman C, The localization of monoaminergic blood-brain mechanism. Pharmacol Rev 18: 369-385, 1966.
77. Lai FM and Spector S, Studies on the monoamine oxidase and catechol-O-methyltransferase of the rat cerebral microvessels. Arch Int Pharmacodyn Ther 233: 227-234, 1978.
78. Lai FM, Udenfriend S and Spector S, Presence of norepinephrine and related enzymes in isolated brain microvessels. Proc Natl Acad Sci USA 72: 4622-4625, 1975.
79. Audus KL and Borchardt RT, Characteristics of the large neutral amino acid transport system of bovine brain microvessel endothelial cell monolayers. J Neurochem 47: 484-488, 1986.
80. Maher F, Vannucci SJ and Simpson IA, Glucose transport proteins in brain. FASEB J 8: 1003-1011, 1994.
81. Su T-Z, Lunney E, Campbell G and Oxender DL, Transport of gabapentin, a γ-ammo acid drug, by system L α-amino acid transporters: A comparative study in astrocytes, synaptosomes, and CHO cells. J Neurochem 64: 2125-2131, 1995.
82. Antonini A and Stryker P, Rapid remodeling of axonal arbors in the visual cortex. Science 260: 1819-1821, 1993.
83. Sutula T, He XX, Cavazzos J and Scott G, Synaptic reorganization in the hippocampus induced by abnormal functional activity. Science 239: 1147-1150, 1988.
84. 18F]fluorodopamine is enhanced in patients with Parkinson's disease. J Nucl Med 34: 31P, 1993.
85. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34: 423-431, 1993.
86. 18F-DOPA uptake: Absence of an aging effect. J Cereb Blood Flow Metab 13: 881-888, 1993.
87. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD and Frackowiak RSJ, Nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 47: 1290-1298, 1990.
88. Guttman M, Yong VW, Kim SU, Calne DB, Martin WRW, Adam MJ and Ruth TJ, Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys. Synapse 2: 469-473, 1988.
89. Pate B, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, Ruth TJ and Calne DB, Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 34: 331-338, 1993.
90. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34: 324-330, 1993.
91. Barrio JR, Huang SC, Yu DC, Melega WP, Quintana J, Cherry SR, Jacobson A, Namavari M, Satyamurthy N and Phelps ME, Radiofluorinated L-m-tyrosines: New in-vivo probes for central dopamine biochemistry. J Cereb Blood Flow Metab 16: 667-678, 1996.
92. Henry JP and Scherman D, Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem Pharmacol 38: 2395-2404, 1989.
93. Vander Borght TM, Kilbourn MR, Koeppe RA, Da Silva JN, Carey JE, Kuhl DE and Frey KA, In-vivo imaging of brain vesiclar monoamine transporter. J Nucl Med 36: 2252-2260, 1995.
94. 11C]-DOPA in humans studied by positron emission tomography. J Neural Transm [Gen Sect] 86: 25-41, 1991.